Sanofi - Aventis Groupe: Press Release: New nirsevimab data analyses reinforce efficacy against RSV

New nirsevimab data analyses reinforce efficacy against RSV A prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory

Related Keywords

Paris ,France General ,France ,Athens ,Attikír ,Greece ,Japan ,United Kingdom ,Philadelphia ,Pennsylvania ,United States ,China ,California ,Eva Schaefer Jansen ,Nicolas Obrist ,Corentine Driancourt ,Peric Sim ,Felix Lauscher ,Kate Conway ,Nathalie Pham ,Sandrine Guendoul ,Sally Bain ,Priya Nanduri ,Nasdaq ,European Society For Paediatric Infectious Diseases ,Global Head Of Research ,Astrazeneca ,California Perinatal Association ,Burden Of Community ,Japan Agency For Medical Research ,China Center ,Centers For Disease ,Drug Administration ,Regulatory Agency ,Uc Denver School Of Medicine ,National Medical Products Administration ,European Medicines Agency Ema Priority ,Development Vaccines ,Euronext ,European Society ,Paediatric Infectious Diseases ,Pediatrics Infectious Diseases ,Vice President ,Annual Meeting ,Collaboration Revenue ,Breakthrough Therapy Designation ,Drug Evaluation ,European Medicines Agency ,Promising Innovative Medicine ,United Kingdom Medicines ,Drug Selection ,Promote New Drug Development ,Japan Agency ,Medical Research ,New England Journal ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Healthy Late ,Single Dose Nirsevimab ,Medically Attended ,Healthy Late Preterm ,Term Infants ,Accessed May ,Healthy Preterm ,Medically Attended Respiratory Syncytial Virus ,Lower Respiratory Track Infection ,Disease Control ,California Perinatal ,Sanofi ,Eventis ,Roupe ,Dress ,Release ,Nirsevimab ,Data ,Analyses ,Reinforce ,Efficacy ,Against ,